By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK genotoxicity assay firm Gentronix and French personalized medicine company BioQuanta SA recently announced a deal for the commercialization of services based on BioQuanta's Mitoxis functional metabolomics platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.